Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Buy” from Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been given an average recommendation of “Buy” by the fourteen analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $112.0833.

Several brokerages recently issued reports on MNPR. Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research note on Thursday, July 23rd. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Finally, BTIG Research lifted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th.

Monopar Therapeutics Trading Up 3.0%

Shares of MNPR opened at $111.64 on Tuesday. The company’s fifty day simple moving average is $86.42 and its 200 day simple moving average is $68.65. Monopar Therapeutics has a 1-year low of $29.18 and a 1-year high of $116.68. The company has a market cap of $747.99 million, a price-to-earnings ratio of -58.76 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. As a group, research analysts forecast that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics in the third quarter valued at about $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics in the 4th quarter valued at about $65,000. JPMorgan Chase & Co. grew its stake in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Monopar Therapeutics in the 2nd quarter valued at about $80,000. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.